Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.2K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

10.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

6.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

4.7K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

CDO1 is a new biomarker to discriminate aggressive forms of prostate cancer.

Oncogene·2026
Same author

Tumor-targeted bispecific antibodies effectively inhibit oncogenic pathways while minimizing toxicity.

Science advances·2026
Same author

Robot-assisted versus open surgery for multiple ipsilateral renal tumors: a multicenter matched cohort study (UroCCR-60).

Journal of robotic surgery·2026
Same author

Patient-reported outcomes and experiences in outpatient vs inpatient robot-assisted radical prostatectomy: the BETTY trial.

BJU international·2026
Same author

Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate Cancer.

European urology oncology·2026

Related Experiment Video

Updated: May 7, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

20.8K

PI3K/AKT pathway activation in bladder carcinogenesis.

Julien Calderaro1, Sandra Rebouissou, Leanne de Koning

  • 1APHP, Groupe Hospitalier Henri Mondor, Département de Pathologie, 51 avenue du Mal-de-Lattre-de-Tassigny, 94010, Créteil, France; INSERM, U955, Institut Mondor de Recherche Biomédicale, 94010, Créteil, France; Université Paris-Est Créteil, 94010, Créteil, France.

International Journal of Cancer
|October 15, 2013
PubMed
Summary

The PI3K/AKT pathway is activated in all bladder urothelial carcinomas (UC), irrespective of stage or common molecular changes. This activation is independent of PTEN expression levels, suggesting a broad role in bladder cancer development.

Keywords:
PI3K/AKT pathwayPTENRPPAbladdercarcinomaphospho-S6 ribosomal protein

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.2K
Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

9.8K

Related Experiment Videos

Last Updated: May 7, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

20.8K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.2K
Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

9.8K

Area of Science:

  • Oncology
  • Molecular Biology
  • Urology

Background:

  • The PI3K/AKT pathway is crucial in bladder cancer development.
  • Its relationship with other molecular alterations in bladder cancer is not fully understood.

Purpose of the Study:

  • To investigate PI3K/AKT pathway activation in bladder urothelial carcinomas (UC).
  • To explore the associations between pathway activation, PTEN status, and common gene mutations (FGFR3, PIK3CA, KRAS, HRAS, NRAS, TP53).

Main Methods:

  • Analyzed 129 UC samples and 6 normal bladder tissues.
  • Assessed phospho-AKT (pAKT), phospho-S6 (pS6), and PTEN expression using reverse phase protein array.
  • Evaluated miR-21, miR-19a, and miR-222 expression.
  • Correlated protein and microRNA expression with PTEN deletions and gene mutations.

Main Results:

  • pAKT levels were elevated in tumors compared to normal urothelium and correlated with pS6.
  • No association was found between pAKT/pS6 and the studied gene mutations.
  • PTEN expression decreased in advanced tumors and PTEN-deleted samples, correlating negatively with miR-19a and miR-222.
  • A positive correlation was observed between pAKT and PTEN expression in early-stage tumors (Ta and T1).

Conclusions:

  • PI3K/AKT pathway activation is a common event across all stages of bladder UC.
  • This activation appears independent of PTEN expression and most frequent molecular alterations.
  • The findings highlight the broad significance of the PI3K/AKT pathway in bladder carcinogenesis.